M. Étienne-Grimaldi

发表

Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02)

F. Bertucci, P. Finetti, P. Giraud, 2012, Clinical Cancer Research.

Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study

F. Lévi, G. Milano, P. Innominato, 2017, Clinical Pharmacokinetics.

Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma

M. Etienne-Grimaldi, E. Saâda-Bouzid, J. Guigay, 2023, Current opinion in oncology.

Pharmacokinetics of sunitinib in hemodialysis.

G. Milano, M. Etienne-Grimaldi, H. Izzedine, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

H. Lenz, S. Im, Q. Wei, 2011, Clinical Cancer Research.

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

J. Douillard, G. Milano, M. Etienne-Grimaldi, 2012, British journal of clinical pharmacology.

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

J. Gaudart, G. Milano, L. Ouafik, 2011, BMC Cancer.

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.

F. Penault-Llorca, A. Bozec, G. Milano, 2008, European journal of cancer.

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

P. Laurent-Puig, C. Létoublon, G. Milano, 2008, Clinical Cancer Research.

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

G. Milano, P. Hofman, M. Merlano, 2007, Journal of Cancer Research and Clinical Oncology.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

G. Milano, L. Mineur, M. Etienne-Grimaldi, 2010, British journal of clinical pharmacology.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.

M. Loriot, N. Pallet, V. Boige, 2022, European journal of cancer.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

M. Loriot, C. Ged, M. Gaub, 2015, Fundamental & clinical pharmacology.

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

M. Loriot, C. Ged, M. Gaub, 2014, Bulletin du cancer.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

Mira Ayadi, Pierre Laurent-Puig, Aurélien de Reyniès, 2013, PLoS medicine.

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2008, British Journal of Cancer.

Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

N. Magné, F. Demard, X. Pivot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

A. Bozec, G. Milano, M. Etienne-Grimaldi, 2011, Oral oncology.

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

N. Magné, G. Poissonnet, O. Dassonville, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.

J. Thariat, G. Milano, M. Etienne-Grimaldi, 2012, Cancer Treatment Reviews.

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.

G Milano, C. Létoublon, G. Milano, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma

V. Servois, B. Asselain, F. Bidard, 2016, The oncologist.

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

M. Namer, G. Milano, R. Largillier, 2006, Clinical Cancer Research.

High-resolution analysis of DNA copy number alterations in rectal cancer

E. Letouzé, G. Milano, J. Gaedcke, 2014, Strahlentherapie und Onkologie.

Frequent intragenic rearrangements of DPYD in colorectal tumours

P. Laurent-Puig, C. Létoublon, G. Milano, 2014, The Pharmacogenomics Journal.